To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight/obese patients.
BMI: ≤ 35 kg/m² and ≥ 30 kg/m², or ≥ 27 kg/m² and having at least one obesity-related complication (such as hypertension, type 2 diabetes, dyslipidemia)
Voluntarily sign the informed consent form, agreeing to cooperate in completing the 24-week treatment and follow-up.
No severe cognitive impairment or mental illness, and able to understand and comply with the research requirements.
Allergy to liraglutide, orlistat or excipients
Severe liver and kidney dysfunction: ALT or AST> three times the upper limit of normal, or eGFR <30 mL/min
Thyroid diseases: Personal or family history of medullary thyroid cancer, or uncontrolled hyperthyroidism/hypothyroidism
Gastrointestinal diseases: Having gastrointestinal surgery within 3 months, or inflammatory bowel disease or active gastric and duodenal ulcers